Alumis Inc. (NASDAQ:ALMS) CEO Martin Babler Purchases 15,650 Shares

Alumis Inc. (NASDAQ:ALMS - Get Free Report) CEO Martin Babler purchased 15,650 shares of the business's stock in a transaction dated Tuesday, April 1st. The stock was bought at an average cost of $6.44 per share, for a total transaction of $100,786.00. Following the purchase, the chief executive officer now owns 106,454 shares in the company, valued at $685,563.76. This trade represents a 17.23 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Alumis Trading Down 26.5 %

Shares of NASDAQ ALMS traded down $2.67 during mid-day trading on Tuesday, reaching $7.40. 882,835 shares of the company's stock were exchanged, compared to its average volume of 315,163. Alumis Inc. has a twelve month low of $3.18 and a twelve month high of $13.53. The business has a fifty day simple moving average of $5.62 and a 200 day simple moving average of $8.15.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ALMS shares. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Alumis in a report on Wednesday, March 26th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Alumis in a research note on Thursday, March 20th. Finally, Oppenheimer started coverage on shares of Alumis in a research note on Thursday, January 30th. They set an "outperform" rating and a $32.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $26.00.

Institutional Trading of Alumis

Hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new position in shares of Alumis in the third quarter valued at approximately $27,000. MetLife Investment Management LLC bought a new stake in Alumis in the 3rd quarter valued at $89,000. Wells Fargo & Company MN boosted its stake in Alumis by 77.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock worth $69,000 after purchasing an additional 3,823 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Alumis during the 4th quarter worth about $79,000. Finally, Marshall Wace LLP acquired a new stake in shares of Alumis in the 4th quarter valued at about $108,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.